Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Nat Chem Biol. 2013 Dec 22;10(2):113–121. doi: 10.1038/nchembio.1429

Figure 3. WWL113 treatment corrects multiple features of metabolic syndrome in db/db mice.

Figure 3

8-week-old db/db mice (n = 10 per group) were dose orally once a day with vehicle, 30 mg/kg WWL113, or 4 mg/kg rosiglitazone. (a) WWL113-treated db/db mice put on weight at a slower rate. (b) Blood chemistry after 3 weeks of WWL113 treatment. WWL113 treatment lowers circulating glucose, free fatty acids (NEFA), triglycerides (TGs), and total cholesterol. (c) WWL113 enhances glucose tolerance after 8 days of treatment in animals of equivalent weight. Glucose tolerance test (1 g/kg intraperitoneal injection), n = 10 per group. (d) Complete clearance of hepatic lipids in db/db mice treated with WWL113 for 3 months (Hematoxylin and Eosin staining showing two representative animals per group). Scale bar = 100 μm. In all cases, error bars represent s.e.m. and *p < 0.05, **p < 0.01, and ***p < 0.001 vs. vehicle-treated mice.